These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32813923)

  • 1. Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources.
    Edelmann D; Ohneberg K; Becker N; Benner A; Schumacher M
    Cancer Med; 2020 Oct; 9(20):7398-7406. PubMed ID: 32813923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Clinical Cohort Data Using Nested Case-control and Case-cohort Sampling Designs. A Powerful and Economical Tool.
    Ohneberg K; Wolkewitz M; Beyersmann J; Palomar-Martinez M; Olaechea-Astigarraga P; Alvarez-Lerma F; Schumacher M
    Methods Inf Med; 2015; 54(6):505-14. PubMed ID: 26108707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sampling strategies to evaluate the prognostic value of a new biomarker on a time-to-event end-point.
    Graziano F; Valsecchi MG; Rebora P
    BMC Med Res Methodol; 2021 Apr; 21(1):93. PubMed ID: 33941092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of incidence and prognosis from 'extreme' case-control designs.
    Salim A; Ma X; Fall K; Andrén O; Reilly M
    Stat Med; 2014 Dec; 33(30):5388-98. PubMed ID: 24980445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new comparison of nested case-control and case-cohort designs and methods.
    Kim RS
    Eur J Epidemiol; 2015 Mar; 30(3):197-207. PubMed ID: 25446306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sampling designs for rare time-dependent exposures: a comparison of the nested exposure case-control design and exposure density sampling.
    Feifel J; von Cube M; Ohneberg K; Ershova K; Wolkewitz M; Beyersmann J; Schumacher M
    Epidemiol Infect; 2021 Apr; 149():e122. PubMed ID: 33888170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goodness-of-fit two-phase sampling designs for time-to-event outcomes: a simulation study based on New York University Women's Health Study for breast cancer.
    Lee M; Chen J; Zeleniuch-Jacquotte A; Liu M
    BMC Med Res Methodol; 2023 May; 23(1):119. PubMed ID: 37208600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk prediction measures for case-cohort and nested case-control designs: an application to cardiovascular disease.
    Ganna A; Reilly M; de Faire U; Pedersen N; Magnusson P; Ingelsson E
    Am J Epidemiol; 2012 Apr; 175(7):715-24. PubMed ID: 22396388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic inference in general nested case-control designs.
    Feifel J; Dobler D
    Biometrics; 2021 Mar; 77(1):175-185. PubMed ID: 32145031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and asymptotic theory for nested case-control designs under highly stratified proportional hazards models.
    Goldstein L; Langholz B
    Lifetime Data Anal; 2023 Apr; 29(2):342-371. PubMed ID: 36472759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Privacy-preserving analysis of time-to-event data under nested case-control sampling.
    Juwara L; Yang YA; Velly AM; Saha-Chaudhuri P
    Stat Methods Med Res; 2024 Jan; 33(1):96-111. PubMed ID: 38093410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External comparisons from nested case-control designs.
    Suissa S; Edwardes MD; Boivin JF
    Epidemiology; 1998 Jan; 9(1):72-8. PubMed ID: 9430272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight calibration to improve the efficiency of pure risk estimates from case-control samples nested in a cohort.
    Shin YE; Pfeiffer RM; Graubard BI; Gail MH
    Biometrics; 2020 Dec; 76(4):1087-1097. PubMed ID: 31863593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the matched extreme case-control design more powerful than the nested case-control design?
    Støer NC; Salim A; Bokenberger K; Karlsson I; Reilly M
    Stat Methods Med Res; 2019 Jun; 28(6):1911-1923. PubMed ID: 29927359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators.
    JAMA; 1995 Nov 22-29; 274(20):1591-8. PubMed ID: 7474243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crude incidence in two-phase designs in the presence of competing risks.
    Rebora P; Antolini L; Glidden DV; Valsecchi MG
    BMC Med Res Methodol; 2016 Jan; 16():5. PubMed ID: 26754746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of cohort sampling designs: some surprising results.
    Langholz B; Thomas DC
    Biometrics; 1991 Dec; 47(4):1563-71. PubMed ID: 1786329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A full competing risk analysis of hospital-acquired infections can easily be performed by a case-cohort approach.
    Wolkewitz M; Palomar-Martinez M; Olaechea-Astigarraga P; Alvarez-Lerma F; Schumacher M
    J Clin Epidemiol; 2016 Jun; 74():187-93. PubMed ID: 26633600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nested exposure case-control sampling: a sampling scheme to analyze rare time-dependent exposures.
    Feifel J; Gebauer M; Schumacher M; Beyersmann J
    Lifetime Data Anal; 2020 Jan; 26(1):21-44. PubMed ID: 30426275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented case-only designs for randomized clinical trials with failure time endpoints.
    Dai JY; Zhang XC; Wang CY; Kooperberg C
    Biometrics; 2016 Mar; 72(1):30-8. PubMed ID: 26347982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.